NewAmsterdam Pharma
NAMS
NAMS
32 hedge funds and large institutions have $692M invested in NewAmsterdam Pharma in 2023 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 9 increasing their positions, 5 reducing their positions, and 7 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
32
Holders Change
-3
Holders Change %
-8.57%
% of All Funds
0.47%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.06%
New
4
Increased
9
Reduced
5
Closed
7
Calls
$13.4M
Puts
–
Net Calls
+$13.4M
Net Calls Change
+$10.7M
Top Buyers
1 |
Goldman Sachs
New York
|
+$15.5M |
2 |
Millennium Management
New York
|
+$3.14M |
3 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$2.96M |
4 |
![]()
Adage Capital Partners
Boston,
Massachusetts
|
+$1.12M |
5 |
Morgan Stanley
New York
|
+$619K |
Top Sellers
1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$12.7M |
2 |
Janus Henderson Group
London,
United Kingdom
|
-$3.97M |
3 |
EP
Eversept Partners
New York
|
-$3.2M |
4 |
![]()
Ensign Peak Advisors
Salt Lake City,
Utah
|
-$2.75M |
5 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$416K |